RxDoctor Payments Data

Jeffrey Spier, MD

Urology · El Paso, TXNPI 1033222906

Payments from drug & device makers

$85,140in general payments, 2019–2025

Across 573 payments — averaging $148.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$23K
  • Novartis$15K
  • Pfizer$10K
  • Bayer$9K
  • Johnson & Johnson$7K
  • Siemens Medical Solutions USA, Inc.$6K
  • plus $16K from 39 others

What the payments were for

  • Consulting fees$50,65666%
  • Travel & lodging$9,25012%
  • Food & beverage$16,96222%
  • Education$3520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$85,140 in reported general payments places this provider in the 90th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$783,586
Medicare patients
749
Services billed
11,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide350$5,209,986
XtandiEnzalutamide154$2,196,041
NubeqaDarolutamide144$1,913,765
OrgovyxRelugolix229$595,101
MyrbetriqMirabegron85$87,293
Abiraterone Acetate60$63,574
Tamsulosin Hcl792$13,493
Mirabegron ErMirabegron14$10,220
Solifenacin Succinate150$7,470
Finasteride330$4,242
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst118$3,074
NitrofurantoinNitrofurantoin Macrocrystal45$1,710
Silodosin26$1,709
Ciprofloxacin Hcl308$1,667
Testosterone Cypionate27$1,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$6,528$5,209,986350 claims
Astellas Pharma US IncXtandi, Myrbetriq$1,465$2,283,333239 claims
BayerNubeqa$9,304$1,913,765144 claims
Sumitomo Pharma America, Inc.Orgovyx$528$595,101229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 878 urology providers in Texas.

Other urology in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →